Descriptive Epidemiology of Ependymal Tumors in Gironde, France: Results from the Gironde Registry for the 2000-2018 Period.


Journal

Neuroepidemiology
ISSN: 1423-0208
Titre abrégé: Neuroepidemiology
Pays: Switzerland
ID NLM: 8218700

Informations de publication

Date de publication:
2022
Historique:
received: 09 09 2021
accepted: 10 02 2022
pubmed: 24 3 2022
medline: 9 9 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

The Gironde Central Nervous System (CNS) Tumor Registry, in collaboration with the French National Cancer Institute, is the largest population-based registry focused exclusively on primary CNS tumors in France and represents a population of 1.62 million. This report focuses on ependymal tumors to refine current knowledge and provide up-to-date data on the epidemiology of these rare tumors. All of the ependymal tumors were extracted from the Gironde CNS Tumor Registry for the years 2000-2018. Demographic and clinical characteristics, incidence rates, and time trends as well as survival outcomes were analyzed. One hundred forty-four ependymal tumors were retrieved, which represented 2.3% of all the CNS tumors recorded in the same period. Histological subtype was significantly dependent on age and topography in the CNS. The median age at diagnosis was 46 years. The annual incidence rates varied between 0.15/100,000 (2004) and 0.96/100,000 (2016), with a significant increase over the study period by 4.67% per year. Five-year and 10-year OS rates were 87% and 80%, respectively. An increase in the incidence of ependymal tumors was observed over the past two decades. Further studies are needed to confirm this result and provide etiological clues.

Sections du résumé

BACKGROUND
The Gironde Central Nervous System (CNS) Tumor Registry, in collaboration with the French National Cancer Institute, is the largest population-based registry focused exclusively on primary CNS tumors in France and represents a population of 1.62 million. This report focuses on ependymal tumors to refine current knowledge and provide up-to-date data on the epidemiology of these rare tumors.
MATERIAL AND METHODS
All of the ependymal tumors were extracted from the Gironde CNS Tumor Registry for the years 2000-2018. Demographic and clinical characteristics, incidence rates, and time trends as well as survival outcomes were analyzed.
RESULTS
One hundred forty-four ependymal tumors were retrieved, which represented 2.3% of all the CNS tumors recorded in the same period. Histological subtype was significantly dependent on age and topography in the CNS. The median age at diagnosis was 46 years. The annual incidence rates varied between 0.15/100,000 (2004) and 0.96/100,000 (2016), with a significant increase over the study period by 4.67% per year. Five-year and 10-year OS rates were 87% and 80%, respectively.
CONCLUSION
An increase in the incidence of ependymal tumors was observed over the past two decades. Further studies are needed to confirm this result and provide etiological clues.

Identifiants

pubmed: 35320802
pii: 000523954
doi: 10.1159/000523954
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

250-260

Informations de copyright

© 2022 S. Karger AG, Basel.

Auteurs

Gaëtan Laine (G)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Isabelle Baldi (I)

Bordeaux Population Health Research Center, Team Epicene, UMR 1219, University of Bordeaux, INSERM, Bordeaux, France.

Vincent Jecko (V)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Zamira Betancourt (Z)

Bordeaux Population Health Research Center, Team Epicene, UMR 1219, University of Bordeaux, INSERM, Bordeaux, France.

Emilie Bertaud (E)

Bordeaux Population Health Research Center, Team Epicene, UMR 1219, University of Bordeaux, INSERM, Bordeaux, France.

Aymeri Huchet (A)

Department of Radiation Oncology, CHU de Bordeaux, Bordeaux, France.

Patrice Menegon (P)

Department of Neuroradiology, CHU de Bordeaux, Bordeaux, France.

Sandrine Eimer (S)

Department of Pathology, CHU de Bordeaux, Bordeaux, France.

Guillaume Chotard (G)

Department of Pathology, CHU de Bordeaux, Bordeaux, France.

Emmanuel Cuny (E)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Edouard Gimbert (E)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Dominique Liguoro (D)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Olivier Mollier (O)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Pascal Monteil (P)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Guillaume Penchet (G)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Jean-Rodolphe Vignes (JR)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Thomas Wavasseur (T)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Hugues Loiseau (H)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Julien Engelhardt (J)

Department of Neurosurgery, CHU de Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH